A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers

Trial Profile

A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Aug 2018

At a glance

  • Drugs Molibresib (Primary)
  • Indications Carcinoma; Colorectal cancer; Multiple myeloma; Neuroblastoma; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Jul 2018 This study has been completed in France.
    • 02 Feb 2018 Planned End Date changed from 9 Sep 2019 to 14 Dec 2019.
    • 02 Feb 2018 Planned primary completion date changed from 11 Mar 2019 to 13 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top